Gastric Neuroendocrine Tumors: Reappraisal of Type in Predicting Outcome.

Annals of Surgical Oncology
Andrew HannaRobert E Roses

Abstract

Type I gastric neuroendocrine tumors (GNETs) are typically managed either expectantly or endoscopically. In contrast, locoregional surgery has been recommended for patients with type III GNETs because of the risk of metastasis. This study aimed to identify predictors of outcome independent of type in a contemporary cohort of GNET patients. A single-institution retrospective cohort study of 121 patients with a pathologic diagnosis of primary GNET between January 2009 and June 2019 was performed. GNETs were designated as type 1 (n = 74) if atrophic gastritis was present, or as type III (n = 47) in the absence of atrophic gastritis. Demographic, clinical, and histopathologic factors were examined using Kaplan-Meier and multivariable Cox regression to assess the impact of various factors on recurrence and overall survival. Median follow-up for the entire cohort was 62.7 months. While there was no difference in OS in patients with different GNET types (p = 0.10), higher tumor grade (p = 0.02) and presence of nodal or distant metastases (p = 0.02) predicted worse survival on multivariable analysis. Among type III GNET patients, those with small (< 0.5 cm), grade 1 lesions ("low-risk") were less likely to develop metastases (0% versus...Continue Reading

References

Feb 6, 2003·Cancer·Irvin M ModlinMark Kidd
Dec 23, 2003·The American Journal of Gastroenterology·Irvin M ModlinMark Kidd
Oct 25, 2006·Alimentary Pharmacology & Therapeutics·M D Burkitt, D M Pritchard
Feb 22, 2007·Neuroendocrinology·Philippe RuszniewskiUNKNOWN European neuroendocrine Tumor Society
Apr 17, 2007·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·D RavizzaC Crosta
Oct 28, 2008·Annals of Surgical Oncology·Christine S LandryRobert C G Martin
May 14, 2009·World Journal of Gastroenterology : WJG·Sara MassironiDario Conte
Sep 4, 2009·Annals of Surgical Oncology·Rebecca A GladdyLaura H Tang
Feb 26, 2011·Endocrinology and Metabolism Clinics of North America·Ben LawrenceIrvin M Modlin
Nov 8, 2012·European Journal of Endocrinology·Dimitrios ThomasGregory Kaltsas
Jan 9, 2013·International Surgery·Shunji EndoJunichi Nishijima
Apr 16, 2013·Best Practice & Research. Clinical Gastroenterology·M FraenkelG D Valk
Apr 18, 2013·Pancreas·Pamela L KunzUNKNOWN North American Neuroendocrine Tumor Society
Oct 30, 2013·Journal of Surgical Oncology·Ahmet UygunSait Bagci
Nov 6, 2013·Digestive Endoscopy : Official Journal of the Japan Gastroenterological Endoscopy Society·Yuichi SatoKen Haruma
Jan 1, 2014·World Journal of Gastroenterology : WJG·Yong Hwan KwonJeong Seop Moon
Mar 19, 2014·Alimentary Pharmacology & Therapeutics·R BasuroyJ K Ramage
Oct 14, 2014·Scandinavian Journal of Gastroenterology·Edith LahnerBruno Annibale
Jan 20, 2016·Neuroendocrinology·G Delle FaveUNKNOWN Vienna Consensus Conference participants
Oct 22, 2016·Journal of Surgical Oncology·Lauren M PostlewaitShishir K Maithel
Aug 2, 2017·American Journal of Clinical Oncology·Ann F CallahanLaleh Melstrom
Jun 13, 2018·The British Journal of Surgery·B-H MinJ J Kim
May 12, 2020·Alimentary Pharmacology & Therapeutics·Klaire ExarchouDavid Mark Pritchard
Jun 25, 2020·Digestive Endoscopy : Official Journal of the Japan Gastroenterological Endoscopy Society·Toshiaki HirasawaTakeshi Sano
Sep 4, 2020·World Journal of Gastrointestinal Oncology·Gabriel Antonio RobertoRiad Naim Younes

❮ Previous
Next ❯

Citations

Jun 19, 2021·Annals of Surgical Oncology·Andrew Hanna, Robert E Roses

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrophic Gastritis

Atrophic Gastritis is a process where gastric glandular cells are lost and replaced with firbous tissues, as a result of chronic inflammation. Learn more about Atrophic Gastritis here.